CNC vs PPCB · P/E 8.4, rev $163.07B vs P/E 0.0, $3.9M cap
Centene Corp (CNC) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Centene Corp (CNC) is a healthcare plans company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported CNC revenue for 2024-12-31 was $163.07B. Net income was $3.29B. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
PPCB does not have a complete income-statement cache yet.
CNC currently screens at market cap $28.19B and trailing P/E 8.4. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the CNC and PPCB stock pages for the full models.
Not investment advice.